Month: May 2024

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for up to $1.01 billion in milestones and royalties under license agreement – – Initiated dosing in a first-in-human Phase 1 clinical trial with ARV-102, the first oral PROTAC® degrader in clinical development to treat neurodegenerative diseases – NEW HAVEN, Conn., May 07, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer’s disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multiple anticipated value-creating catalysts WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced financial results for the first quarter ended...

Harvard Bioscience Announces First Quarter 2024 Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of 60%. After quarter end, we announced a cost reduction initiative to improve our operating cost structure and support our ongoing investments in growth.” Green continued, “Looking ahead, we are excited by our growth strategy and new product commercializations. Together with the new round of Chinese stimulus targeting...

GlobalFoundries Reports First Quarter 2024 Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

MALTA, N.Y., May 07, 2024 (GLOBE NEWSWIRE) — GlobalFoundries Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the first quarter ended March 31, 2024. Key First Quarter Financial HighlightsRevenue of $1.549 billion Gross margin of 25.4% and Non-IFRS gross margin(1) of 26.1% Operating margin of 9.5% and Non-IFRS operating margin(1) of 12.1% Net income of $134 million and Non-IFRS net income(1) of $174 million Non-IFRS EBITDA(1) of $577 million Cash, cash equivalents and marketable securities of $4.2 billion“In the first quarter, GF’s dedicated teams across the world delivered financial results that exceeded the high end of the guidance ranges we provided in our February earnings release,” said Dr. Thomas Caulfield, president and CEO of GF. “As pockets of the semiconductor industry...

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

– Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring Committee- -Presented preclinical data demonstrating the potential synergy between VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft at the ASGCT Annual Meeting; emphasizes VCN-01’s potential in diverse chemotherapy combinations for improved efficacy in pancreatic cancer- – VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- – As of March 31, 2024, Theriva Biologics reports $18.3 million in cash, which is expected to provide runway into the...

Chicago Atlantic Real Estate Finance Announces First Quarter 2024 Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

CHICAGO, May 07, 2024 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the first quarter ended March 31, 2024. John Mazarakis, Executive Chairman of Chicago Atlantic, noted, “We are thrilled with progress toward regulatory reform resulting from the recent news of the DEA’s commitment to the rescheduling of cannabis. Once enacted, the policy change is likely to bring significant benefits to the U.S. cannabis industry, including the elimination of punitive federal tax burdens, increased access to capital, and increased employment and investment opportunity to the expected benefit of our shareholders. While there is still uncertainty as to exactly how and when the rescheduling will...

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Written by Customer Service on May 7, 2024. Posted in Public Companies.

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that company management will participate in fireside chats at the following investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ETRBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at 11:00 AM ETBank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:40 AM PT The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations. About Lexeo TherapeuticsLexeo...

Amesite Announces Strategic Five-Year Partnership with Franciscan Missionaries of Our Lady University to Deliver Healthcare Training for Healthcare Professionals

Written by Customer Service on May 7, 2024. Posted in Public Companies.

Franciscan Missionaries of Our Lady University is Sixth Contract Win Since Introducing No Setup-fee Plan DETROIT, May 07, 2024 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announces a five-year (5) partnership with Franciscan Missionaries of Our Lady University to deliver healthcare training programs for working healthcare professionals in subjects ranging from leadership and management, quality improvement, healthcare finance, nursing continuing education (CNE), physical therapy continuing education, ethics in medicine and continuing medical education (CME). “As we seek to expand our mission to educate healthcare professionals and form Franciscan servant leaders of all faiths we are honored to partner...

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales$137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan)Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024 On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024 Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operations for foreseeable future Management to host conference call today at 8:30 a.m. ETWALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights. “We made excellent progress against our strategic priorities during the...

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 2024 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2024 and highlighted recent progress across its business. “In the first quarter, we made solid progress across three key...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals